Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.

Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA.

Oncology. 2013;85(4):204-7. doi: 10.1159/000354736. Epub 2013 Sep 19.

PMID:
24051869
2.

Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.

Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA.

J Clin Oncol. 2013 Dec 1;31(34):4306-10. doi: 10.1200/JCO.2013.51.7250. Epub 2013 Oct 21.

3.

Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.

Boggs DH, Tarabolous C, Morris CG, Hanna A, Burrows W, Horiba N, Suntharalingam M.

Dis Esophagus. 2015 Oct;28(7):619-25. doi: 10.1111/dote.12243. Epub 2014 May 26.

PMID:
24863682
4.

Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.

Hategan M, Cook N, Prewett S, Hindmarsh A, Qian W, Gilligan D.

Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27. Review.

PMID:
24863560
5.

Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy?

Rice TW, Khuntia D, Rybicki LA, Adelstein DJ, Vogelbaum MA, Mason DP, Murthy SC, Blackstone EH.

Ann Thorac Surg. 2006 Dec;82(6):2042-9, 2049.e1-2.

PMID:
17126108
6.

Management of late distant metastases after trimodality therapy for esophageal cancer.

Mao YS, Suntharalingam M, Krasna MJ.

Ann Thorac Surg. 2003 Nov;76(5):1742-3.

PMID:
14602333
7.

Incidence of brain metastasis in patients with esophageal carcinoma.

Smith RS, Miller RC.

World J Gastroenterol. 2011 May 21;17(19):2407-10. doi: 10.3748/wjg.v17.i19.2407.

8.

A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.

Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA.

Eur J Cancer. 2012 Dec;48(18):3396-404. doi: 10.1016/j.ejca.2012.06.020. Epub 2012 Jul 31.

9.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
10.

Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.

Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA.

Oncology. 2014;86(5-6):336-9. doi: 10.1159/000360703. Epub 2014 Jun 7.

11.

Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.

Gerber N, Ilson DH, Wu AJ, Janjigian YY, Kelsen DP, Zheng J, Zhang Z, Bains MS, Rizk N, Rusch VW, Goodman KA.

Dis Esophagus. 2014 Apr;27(3):235-41. doi: 10.1111/dote.12082. Epub 2013 Jun 24.

PMID:
23796070
12.

Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.

Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

PMID:
21556952
13.

Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW.

J Clin Oncol. 2010 Nov 1;28(31):4714-21. doi: 10.1200/JCO.2010.30.7702. Epub 2010 Sep 27.

14.

Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.

Chidel MA, Rice TW, Adelstein DJ, Kupelian PA, Suh JH, Becker M.

Radiology. 1999 Oct;213(1):67-72.

PMID:
10540642
15.

Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.

Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG.

Dis Esophagus. 2013 Sep-Oct;26(7):708-15. doi: 10.1111/dote.12019. Epub 2013 Jan 25.

PMID:
23350713
16.

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.

Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93.

PMID:
15590179
17.

Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.

Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K.

Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23.

PMID:
24854492
18.
19.

The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.

Markar SR, Bodnar A, Rosales J, Song G, Low DE.

Ann Surg Oncol. 2013 Nov;20(12):3935-41. doi: 10.1245/s10434-013-3137-9. Epub 2013 Jul 27.

PMID:
23892525
20.

Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.

Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB, Pickens A, Pan CC, Merajver SD, Urba SG.

Invest New Drugs. 2013 Apr;31(2):435-42. doi: 10.1007/s10637-012-9864-0. Epub 2012 Jul 31.

Supplemental Content

Support Center